Samopriyo Maitra Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (6)

4× Novartis Healthcare Private Limited, Hyderabad, India
1× 34Novartis Healthcare Private Limited, Hyderabad, India
1× King's College Hospital NHS, London, United Kingdom
1× 20Novartis Healthcare Private Limited, Hyderabad, India
1× 14Novartis Healthcare Private Limited, Hyderabad, India
1× 10Novartis Healthcare Private Limited, Hyderabad, India

Papers 8 stored

All · Aachen affiliation only

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access

15

citations
Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases

2

citations
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases

1

citations
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases

14

citations
MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases Open access

2

citations
POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia article Immunology and Microbiology Complement system in diseases

0

citations
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
2023 HemaSphere article Immunology and Microbiology Complement system in diseases Open access

2

citations
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
2022 Blood article Immunology and Microbiology Complement system in diseases

23

citations

8 results

Samopriyo Maitra ▲ Sign in to save

Departments & institutes in Aachen

Papers 8 stored

Samopriyo Maitra Sign in to save